{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Number of Subjects to be Enrolled: Up to approximately 740 SCLC subjects, to obtain approximately', '480 subjects with DLL3high expression in tumor (DLL3high DLL3 high is defined as > 75% tumor cells', 'staining positive according to the VENTANA DLL3 (SP347) IHC Assay.', 'Methodology:', 'This is a Phase 3, randomized, double-blinded, placebo-controlled, multinational, and multicenter study.', 'ED SCLC subjects who meet all the inclusion criteria and none of the exclusion criteria, and demonstrate', 'ongoing clinical benefit (SD, PR, or CR) at the completion of 4 cycles of first-line platinum-based', 'chemotherapy (such benefit must be ongoing at the last re-staging assessment prior to randomization),', 'will be randomly assigned in a 1:1 ratio to receive 0.3 mg/kg rovalpituzumab tesirine or placebo, and will', 'receive their assigned therapy on Day 1 of each 6-week cycle, omitting every third cycle. Upon', 'completion of first-line chemotherapy, eligible subjects must be offered prophylactic cranial irradiation', '(PCI), if offering this procedure is not contradictory to country or institutional guidelines. Subjects', 'receiving PCI must complete it prior to randomization into the study. Subjects will also receive 8 mg', 'orally (PO) of dexamethasone or placebo twice daily on Day -1, Day 1, and Day 2 of each 6-week cycle,', 'omitting every third cycle. Randomization will be stratified by RECIST v1.1 response after completion', 'of first-line platinum-based chemotherapy at screening assessment (SD VS. PR/CR), DLL3 expression,', '(Unknown VS. 0% to < 25% VS. 25% to < 75% VS. 75% or above), history of central nervous system', '(CNS) metastases (Yes VS. No), and for subjects with no history of CNS metastases, PCI VS. no PCI.', 'Survival Follow-up will continue until the endpoint of death, the subject becomes lost to follow-up or', 'withdraws consent, or termination of the study by AbbVie, whichever occurs first.', 'Diagnosis and Main Criteria for Inclusion/Exclusion:', 'Main Inclusion:', '1.', \"Subject or the subject's legally acceptable representative must voluntarily sign and date an informed\", 'consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB),', 'prior to the initiation of any screening or study-specific procedures and should be willing and able to', 'comply with parameters as outlined in the protocol.', '2.', 'Subject must be > 18 years of age.', '3. Histologically or cytologically confirmed ED SCLC (extensive stage disease at initial diagnosis),', 'with ongoing clinical benefit (SD, PR, or CR per RECIST v1.1) following completion of 4 cycles of', 'first-line platinum-based therapy (cisplatin or carboplatin in combination with etoposide or', 'irinotecan).', '4. Subjects with a history of CNS metastases prior to the initiation of first-line platinum-based', 'chemotherapy must have received definitive local treatment and have documentation of stable or', 'improved CNS disease status based on brain imaging within 28 days prior to randomization, off or on', 'a stable dose of corticosteroids.', '5.', 'Subject is eligible to be randomized at least 3 but no more than 9 weeks from Day 1 of the', 'fourth cycle of first-line platinum-based chemotherapy', '6.', 'Availability of archived or representative tumor material for assessment of DLL3 expression.', '7. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.', '8.', 'Recovery to VI Grade 1 of any clinically significant toxicity (excluding alopecia) prior to', 'randomization.', '11']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):', 'Main Inclusion (Continued):', '9. Subject must have adequate bone marrow, renal and hepatic function as follows:', 'a.', 'Absolute neutrophil count (ANC) > 1,000/L', 'b.', 'Platelet count > 75,000/L', 'c.', 'Hemoglobin > 8.0 g/dL', 'd. Serum total bilirubin < 1.5 X upper limit of normal (ULN) or < 3 X ULN for subjects with', \"Gilbert's disease\", 'e.', 'Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <3 X ULN', '(< 5x ULN if evidence of hepatic involvement by malignant disease)', 'f.', 'Calculated creatinine clearance > 30 mL/min by the modified Cockroft-Gault formula (Refer to', 'Appendix E).', 'g.', 'Albumin > 3g/dL', '10. If female, subject must be either postmenopausal as defined as:', 'Age > 55 years with no menses for 12 or more months without an alternative medical cause.', 'Age < 55 years with no menses for 12 or more months without an alternative medical cause', 'AND an FSH level > 40 IU/L.', 'OR', 'Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).', 'OR a Women of Childbearing Potential (WOCBP) practicing at least one protocol specified method', 'of birth control, starting at randomization through at least 6 months after the last dose of blinded', 'investigational product.', 'If the male subject is sexually active, he must agree, from randomization through at least 6 months', 'after the last dose of blinded investigational product, to practice the protocol specified contraception.', '11. Females of childbearing potential must have a negative serum pregnancy test result at Screening, and', 'a negative urine pregnancy test at randomization.', 'Females of non-childbearing potential (either postmenopausal or permanently surgically sterile as', 'defined in the protocol) at Screening do not require pregnancy testing.', 'Main Exclusion:', '1. Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other', 'monoclonal antibodies, antibody-drug conjugates, adioimmunoconjugates, T-cell or other cell-based', 'or biologic therapies, or any other anti-cancer therapy than that described in Inclusion Criteria 3 - 5', 'for SCLC.', '2.', 'Any disease-directed radiotherapy (except, PCI, palliative radiotherapy to a radiographically', 'documented non-progressing lesion for symptom control, or pre-planned radiotherapy for CNS', 'metastases present prior to start of first-line therapy and non-progressing) after last dose of first-line', 'chemotherapy.', '3. Any significant medical condition including any suggested by screening laboratory findings that in', 'the opinion of the Investigator or Sponsor may place the subject at undue risk from the study.', '12']\n\n###\n\n", "completion": "END"}